Provided By GlobeNewswire
Last update: Sep 8, 2025
EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide and Abaloparatide
Read more at globenewswire.com